Company intelligence / Profile preview

Vector BioMed

Gaithersburg, Maryland, United Statesvectorbiomed.com ↗

Ownership: Private
Development stage: Commercial

Overview

Vector BioMed is not developing its own clinical-stage therapeutics but provides high-quality lentiviral vectors to enable gene and cell therapy development. Their team has extensive experience in the field, including involvement in the first FDA-approved CAR-T cell therapy Kymriah®. They have produced thousands of pre-clinical and hundreds of GMP lentiviral vector batches for various clients.

Modalities: Lentiviral vectorGene therapy (as supported modality)
Industry: Contract Manufacturing Organization

Partnerships

Caring Cross

Beyond the preview

Go deeper on Vector BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vector BioMed.

Explore the full profile